Skip to main content
Sign In

James "Jay" R. Burton, Jr., MD

Associate Professor of Medicine


Associate Professor of Medicine
Medical Director of Liver Transplantation

Medical School: University of Washington School of Medicine, Seattle, WA; 1993-97
Residency: Internal Medicine, Strong Memorial Hospital, Rochester, NY; 1997-2000
Fellowship: Hepatology, Strong Memorial Hospital, Rochester, NY; 2000-2001 and
Gastroenterology, Oregon Health & Science University, Portland, OR; 2001-2004
Board Certified: Internal Medicine, Gastroenterology and Transplant Hepatology

Peak Performer Award, 2009
Present at 7th Annual Rocky Mountain Hospital Medicine Symposium - Recognition in Excellence in GI & Hepatology
AASLD/Schering Advanced Hepatology Fellowship Award, 2003-04
Raphael Dolin Resident Research Award, Dedication to Patient Care, Critical Scholarship and Teaching, June 2000

Faculty Positions
2010-present, Associate Professor of Medicine, University of Colorado Denver
2005-2010, Assistant Professor of Medicine, University of Colorado Denver
Denver, CO
2004-05 Assistant Professor of Medicine, Oregon Health & Science University,
Portland, OR

Clinical Interests:

Dr. Burton is the medical director of liver transplantation at the University of Colorado Hospital. His clinical interests include management of complications of end-stage liver disease (variceal bleeding, ascites and liver cancer) and liver transplantation.

Research interests:

Dr. Burton's research includes retransplantation for recurrent hepatitis C infection and understanding how the immune system responds to hepatitis C virus infection with antiviral therapy and after liver transplantation. He is a coinvestigator on the Adult to Adult Liver Donor Transplant Cohort Study (A2ALL) and many trials of drugs to treat Hepatitis C.

Representative Publications:

1. Burton JR, Klarquist J, Im K, Smyk-Pearson S, Golden-Mason L, Castelblanco N, Terrault NA, Rosen HF. Prospective analysis of effector and regulatory CD4+ T cells in chronic HCV patients undergoing combination antiviral therapy. J Hepatol 2008;49:329-338. (download pdf)

2. McCashland T, Lyden E, Adams L, McGuire B, Burton JR and the US Retransplant Study Group. Is retransplantation for HCV a bad idea? Results of a US multicenter retransplant study. Liver Transpl 2007;13:1246-53. (download pdf)

3. Arjal RR, Burton JR, Villamil, Rosen HR. Review article: the treatment of hepatitis C virus recurrence after liver transplantation. Aliment Pharmacol Ther 2007;26:127-40. (download pdf)

4. Burton JR, Suthat L, Lapidus J, Giannini E, Chalasani N, Zaman A. Validation of a multivariate model predicts presence and size varices. J Clin Gastroenterol 2007;41:609-15. (download pdf)

5. Burton JR, Rosen HR. Acute rejection in HCV-infected liver transplant recipients: the great conundrum. Liver Transpl 2006;12:S38-47. (download pdf)

6. Burton JR, Rosen HR. Diagnosis and management of allograft failure. Clin Liver Dis 2006;10:407-35. (download pdf)

7. Burton JR, Rosen HR. Treatment of HCV recurrence: do the pretransplant rules apply? Liver Transpl 2006;12:1044-8. (download pdf)

8. Burton, JR, Everson GT. HCV NS5B Polymerase Inhibitors. Clin Liver Dis 2009; 13:453-465. (download pdf)